Insider buying last 90 days
No open-market insider purchases were filed for GMED in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every GMED insider filing, plotted on the chart in Gekko.Open GMED in Gekko
NYSE: GMED
Globus Medical (GMED) Stock Analysis & Forecast
Sep 28 close
$74.78+0.26 (+0.3%)
Gekko Brief
AI summaryGMED trades at $74.78, down 9.4% over the past month and off 10.9% over three months, though still up 35.7% over the past year. The close sits below both the 50-day average of $79.60 and the 200-day average of $84.88, with the 50-day below the 200-day, reflecting a period of pressure after the stock's pullback from its 52-week high of $101.40. The GekkoIndex reads 65.2, placing GMED in the Accumulation zone, and the price is close to Gekko Fair Value of $72.37, sitting 3.3% above it.
Looking ahead over the next 20 trading days, GMED's next earnings report is scheduled for 5 November, which falls outside that window; the prior report on 6 August showed non-GAAP EPS of $1.34 against an estimate of $1.10, with a 2.2% reaction, and the company has beaten estimates in 7 of the last 8 quarters. Within the last 90 days, Congress recorded 1 buy and 0 sales. Seasonality data from this point in the calendar shows the next 20 trading days averaging a 4.9% return over 5 years, with gains in 3 of those years. Analyst coverage includes 9 buy ratings and 3 hold ratings among 12 firms, with a consensus target of $103.23.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Globus Medical price vs fair value
Close $74.78200-day averageGekko Fair Value $72.37
Globus Medical quick facts
- Market cap
- $10.09B
- P/E ratio
- 19.1
- Forward P/E
- 13.9
- EPS, TTM
- $3.91
- Revenue, TTM
- $3.14B
- Profit margin
- 17%
- Dividend yield
- —
- Beta
- 0.96
- Volume
- 1.73M avg 1.55M
- 1-year return
- +35.7%
- Typical daily move
- ±2.1%
- Typical 20-day move
- ±5.9%
- 50-day average
- $79.60
- 200-day average
- $84.88
- Next earnings
- Nov 5 after close
- Shares outstanding
- 111.8M
Globus Medical swing-trade checklist
Globus Medical scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed1 headwind
- Trendheadwind
Below 50 and 200-day
Close $74.78 is below the 50-day ($79.60) and 200-day ($84.88) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
65.2, Accumulation
Reading 65.2 is in the Accumulation zone.
See the GekkoIndex - Fair valuemixed
3.3% above
Price is within 5% of Gekko Fair Value (3.3% above).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: Congress 1 buy / 0 sales.
See smart money - Earnings risksupportive
Reports in 37 days
Next report Nov 5, 2026, 37 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+4.9% on average
From this point in the calendar, the next 20 trading days averaged +4.9% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Globus Medical stock chart and price history
Globus Medical closed at $74.78 on Sep 28, 2026, +35.7% over the past year, inside a 52-week range of $55.16 to $101.40.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −9.4%
- 3 months
- −10.9%
- 6 months
- −10.7%
- 1 year
- +35.7%
The full GMED chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open GMED in Gekko
Follow Globus Medical through every session
Put GMED on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track GMED in GekkoFree for 7 days. No credit card required.
About Globus Medical
Globus Medical designs, builds, and sells medical devices used to treat disorders of the bones, joints, and spine. It is best known for its spinal care offerings, which range from fusion hardware such as pedicle screw and rod systems, plating systems, and spacers, to motion-preserving options like disc replacements and dynamic stabilization devices, along with tools for managing vertebral compression fractures.
Its product lines extend beyond the spine into orthopedic trauma care, with plates, screws, nails, and fixation systems for fractures, as well as joint reconstruction devices for the hip and knee, including stems, cups, and arthroplasty implants. The company also supplies regenerative biologic materials, such as allografts and synthetic substitutes, and distributes cell- and tissue-based products, serving patients and clinicians who treat musculoskeletal conditions such as degenerative disease, deformity, tumors, and trauma.
Globus Medical was founded in 2003 and is headquartered in Audubon, Pennsylvania. Its shares are listed on the NYSE under the ticker GMED.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- globusmedical.com
Globus Medical GekkoIndex: the smart money zone
Globus Medical’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 65.2, in the Accumulation zone, down 5 points over five sessions.
65.2Accumulation
Down 5 points over five sessions, from the Buying zone.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 47 | +1.5% | +2.6% | ||
| Accumulation (current zone) | 235 | +0.3% | +1.9% | ||
| Neutral | 328 | +0.2% | +1.9% | ||
| Distribution | 55 | +0.9% | −1.1% | ||
| Selling | 7 | Too few readings yet | |||
Average GMED share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the GMED price, zone by zone.Track GMED in Gekko
Is Globus Medical stock overvalued? Gekko Fair Value
Globus Medical trades 3.3% above Gekko Fair Value of $72.37, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Globus Medical shares are worth, recalculated every trading day.
$72.37
Gekko Fair Value, Sep 29, 2026
3.3% above fair value · About fair value
Gekko Fair Value on every chart, with the gap to price updating daily.Open GMED in Gekko
Globus Medical insider and Congress trading
No open-market insider purchases were filed for Globus Medical, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Gilbert Cisneros House, CA, purchase | $15,001 - $50,000 | Sep 11 traded Aug 19 |
From congressional disclosures, which report amounts as ranges.
Buybacks
Globus Medical has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $136.1M
- As a share of market cap
- 1.35%
From company filings.
Globus Medical earnings: next date and track record
Globus Medical reports on Nov 5, 2026, after the close (37 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected after the close, 37 days away
- EPS estimate
- $1.20
- Revenue estimate
- $792.2M
7 of 8reports beat the EPS estimate
±12.8%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- Globus Medical reported Q2 2026 revenue of $789.6 million, up 6% as reported (9% excluding Nevro). Non-GAAP EPS grew 56% YoY to $1.34, with adjusted EBITDA margin of 35.4%, up 740 bps. U.S. Spine grew 7%, International Spine 14%, and Trauma surged 31%. The company repurchased $136 million in shares and has launched 25+ products over 36 months while continuing aggressive competitive recruiting.
- Guidance
- Management expressed confidence in a strong second half of 2026, citing sustained market share gains, expanding trauma portfolio, Nevro integration, and broad-based organic growth. No specific revenue or EPS targets were provided in this excerpt.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $1.34 est $1.10 | $789.6M est $782.9M | +2.2% |
| May 7, 2026 | $1.12 est $0.92 | $759.9M est $740.3M | −12.6% |
| Feb 24, 2026 | $1.28 est $1.15 | $826.4M est $801.7M | +3.0% |
| Nov 6, 2025 | $1.18 est $0.77 | $769.0M est $734.7M | +36.4% |
| Aug 7, 2025 | $0.86 est $0.75 | $745.3M est $742.7M | +11.0% |
| May 8, 2025 | $0.68 est $0.74 | $598.1M est $625.9M | −21.9% |
| Feb 20, 2025 | $0.84 est $0.75 | $657.3M est $645.7M | −4.5% |
| Nov 5, 2024 | $0.83 est $0.65 | $625.7M est $604.7M | +10.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Globus Medical stock forecast and analyst price targets
Analysts’ average 12-month price target for Globus Medical is $103.23, +38.0% from the last close, from 12 firms rating the stock in the last 90 days.
$103.23consensus 12-month target, +38.0% from the last close
Now $74.78Avg $103.23
Low $82High $117
Each firm’s latest rating in the last 90 days: 12 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 18 | BTIG | — | — |
| Aug 28 | Canaccord Genuity | $115 | +53.8% |
| Aug 27 | BMO Capital | $94 | +25.7% |
| Aug 19 | Bank of America Securities | $106 | +41.7% |
| Aug 11 | Stifel Nicolaus | $85 | +13.7% |
+1.9%average 20-day move after past Accumulation readings
+4.9%average move over the next 20 trading days in the last 5 years
±2.1%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Globus Medical seasonality: the next 20 trading days
Over the next 20 trading days from Sep 26, Globus Medical averaged +4.9% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.4% | 3 of 5 |
| Next 10 trading days | +0.6% | 4 of 5 |
| Next 15 trading days | +5.9% | 4 of 5 |
| Next 20 trading days | +4.9% | 3 of 5 |
| Next 30 trading days | +13.6% | 3 of 5 |
For scale, GMED’s typical 20-trading-day move in either direction is about 5.9%.
Globus Medical market cap and key statistics
Globus Medical’s market cap is $10.09B, with a P/E ratio of 19.1 and revenue of $3.14B over the last twelve months.
Valuation
- Market cap
- $10.09B
- P/E ratio
- 19.1
- Forward P/E
- 13.9
- EPS, TTM
- $3.91
- Gekko Fair Value
- $72.37
Trading
- Volume
- 1.73M
- Avg volume, 20 days
- 1.55M
- 52-week high
- $101.40
- 52-week low
- $55.16
- Shares outstanding
- 111.8M
Financials
- Revenue, TTM
- $3.14B
- Profit margin
- 17%
- Return on equity
- 11.8%
- Quarterly earnings growth, YoY
- −26.2%
Risk and income
- Beta
- 0.96
- Typical daily move
- ±2.1%
- Typical 20-day move
- ±5.9%
Globus Medical peers
Globus Medical’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Distribution | 23.7% above |
| ABTAbbott Laboratories | Accumulation | 15.0% below |
| DHRDanaher | Distribution | 10.2% above |
| ISRGIntuitive Surgical | Neutral | 17.0% above |
| MDTMedtronic | Accumulation | 24.1% below |
| SYKStryker | Accumulation | 14.1% below |
A peer links to its own page where one exists.
Globus Medical stock FAQ
What is Globus Medical’s market cap?
Globus Medical’s market cap is $10.09B at the Sep 28, 2026 close of $74.78, with 111.8M shares outstanding. The shares trade on a P/E ratio of 19.1.
What is the Globus Medical stock forecast?
The consensus analyst 12-month price target for Globus Medical is $103.23, +38.0% from the last close. Of the 12 firms that rated the stock in the last 90 days, 9 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Globus Medical stock overvalued or undervalued?
On Gekko’s estimate Globus Medical is about fair value: the Sep 28, 2026 close of $74.78 is 3.3% above Gekko Fair Value of $72.37. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Globus Medical report earnings next?
Globus Medical is expected to report on Nov 5, 2026, after the market closes (37 days away). Analysts expect earnings of $1.20 per share on revenue of $792.2M. Globus Medical beat the earnings estimate in 7 of its last 8 reports, moving 12.8% on average across the report.
What is Globus Medical’s 52-week high and low?
Globus Medical’s 52-week high is $101.40 and its 52-week low is $55.16; it closed at $74.78 on Sep 28, 2026, +35.7% over the past year.
Is Globus Medical stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, smart money, earnings risk and seasonality), 1 as mixed (fair value) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Globus Medical the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.